ALZAMEND NEURO, INC. Depreciation
ALZAMEND NEURO, INC. (ALZN) reported Depreciation of $27.68 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-09-10
- ALZAMEND NEURO, INC. depreciation for the quarter ending 2026-07-31 was $27.68K, a 0.00% change year-over-year.
- ALZAMEND NEURO, INC. depreciation for the quarter ending 2026-04-30 was $27.68K, a 118.25% increase year-over-year.
- ALZAMEND NEURO, INC. depreciation for the quarter ending 2026-01-31 was $27.68K, a 118.25% increase year-over-year.
- ALZAMEND NEURO, INC. depreciation for the quarter ending 2025-10-31 was $27.68K, a 118.25% increase year-over-year.
- ALZAMEND NEURO, INC. depreciation for fiscal 2026 was $110.74K, a 118.25% increase from fiscal 2025.
- ALZAMEND NEURO, INC. depreciation for fiscal 2025 was $50.74K, a 0.00% change from fiscal 2024.
- ALZAMEND NEURO, INC. depreciation for fiscal 2024 was $50.74K, a 119.98% increase from fiscal 2023.
- ALZAMEND NEURO, INC. depreciation for fiscal 2023 was $23.07K, a 549.93% increase from fiscal 2022.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-07-31 | $27.68K 10-Q · filed 2026-09-10 | $55.37K derived: sum of 2 quarters · filed 2026-09-10 | $83.06K derived: sum of 3 quarters · filed 2026-09-10 | $110.74K derived: sum of 4 quarters · filed 2026-09-10 |
| 2026-04-30 | $27.68K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | $55.37K derived: sum of 2 quarters · filed 2026-07-22 | $83.06K derived: sum of 3 quarters · filed 2026-07-22 | $110.74K 10-K · filed 2026-07-22 |
| 2026-01-31 | $27.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | $55.37K derived: sum of 2 quarters · filed 2026-03-11 | $83.06K 10-Q · filed 2026-03-11 | $95.74K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-10-31 | $27.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | $55.37K 10-Q · filed 2025-12-09 | $68.06K derived: sum of 3 quarters · filed 2026-09-10 | $80.74K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-07-31 | $27.68K 10-Q · filed 2026-09-10 | $40.37K derived: sum of 2 quarters · filed 2026-09-10 | $53.05K derived: sum of 3 quarters · filed 2026-09-10 | $65.74K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-04-30 | $12.69K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | $25.37K derived: sum of 2 quarters · filed 2026-07-22 | $38.05K derived: sum of 3 quarters · filed 2026-07-22 | $50.74K 10-K · filed 2026-07-22 |
| 2025-01-31 | $12.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | $25.37K derived: sum of 2 quarters · filed 2026-03-11 | $38.05K 10-Q · filed 2026-03-11 | $50.74K derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-10-31 | $12.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | $25.37K 10-Q · filed 2025-12-09 | $38.05K derived: sum of 3 quarters · filed 2025-12-09 | $50.74K derived: sum of 4 quarters · filed 2025-12-09 |
| 2024-07-31 | $12.69K 10-Q · filed 2025-09-10 | $25.37K derived: sum of 2 quarters · filed 2025-09-10 | $38.05K derived: sum of 3 quarters · filed 2025-09-10 | $50.74K derived: sum of 4 quarters · filed 2025-09-10 |
| 2024-04-30 | $12.69K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-22 | $25.37K derived: sum of 2 quarters · filed 2025-07-22 | $38.05K derived: sum of 3 quarters · filed 2025-07-22 | $50.74K 10-K · filed 2025-07-22 |
| 2024-01-31 | $12.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-10 | $25.37K derived: sum of 2 quarters · filed 2025-03-10 | $38.05K 10-Q · filed 2025-03-10 | $43.38K derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | $12.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-11 | $25.37K 10-Q · filed 2024-12-11 | $30.69K derived: sum of 3 quarters · filed 2024-12-11 | $36.02K derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-07-31 | $12.69K 10-Q · filed 2024-09-11 | $18.01K derived: sum of 2 quarters · filed 2024-09-11 | $23.33K derived: sum of 3 quarters · filed 2024-09-11 | $28.65K derived: sum of 4 quarters · filed 2024-09-11 |
| 2023-04-30 | $5.32K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $10.65K derived: sum of 2 quarters · filed 2024-07-30 | $15.97K derived: sum of 3 quarters · filed 2024-07-30 | $23.07K 10-K · filed 2024-07-30 |
| 2023-01-31 | $5.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-25 | $10.65K derived: sum of 2 quarters · filed 2024-03-25 | $17.74K 10-Q · filed 2024-03-25 | |
| 2022-10-31 | $5.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-12-15 | $12.42K 10-Q · filed 2023-12-15 | ||
| 2022-07-31 | $7.10K 10-Q · filed 2023-09-13 | |||
| 2022-04-30 | $3.55K 10-K · filed 2023-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |